Evidence map›Paper›PMID 35252893›Full record

ArticleBrain, behavior, & immunity - health2022

Antroquinonol administration in animal preclinical studies for Alzheimer's disease (AD): A new avenue for modifying progression of AD pathophysiology.

Fernandez Francesca, Aust Caitlin, Lye Sarah, Griffiths Lyn Robyn

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain, behavior, & immunity - health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. A modifiable driver of dementia: cognitive impairment in primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fernandez FrancescaSchool of Behavioural and Health Sciences, Faculty of Health Sciences, Australian Catholic University, 1100 Nudgee Rd, Banyo, Queensland, 4014, Australia.
Aust CaitlinSchool of Behavioural and Health Sciences, Faculty of Health Sciences, Australian Catholic University, 1100 Nudgee Rd, Banyo, Queensland, 4014, Australia.
Lye SarahSchool of Behavioural and Health Sciences, Faculty of Health Sciences, Australian Catholic University, 1100 Nudgee Rd, Banyo, Queensland, 4014, Australia.
Griffiths Lyn RobynCentre for Genomics and Personalised Medicine, Genomics Research Centre, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, QLD, 4059, Australia.
Queensland University of Technology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the rise of Alzheimer's disease (AD) in an ageing population, no cure is currently available for this disorder. This study assessed the role of a natural compound, Antroquinonol, in modifying the progression of AD when administered at the start and/or before appearance of symptoms and when the disease was well established, in a transgenic animal model. Antroquinonol was administered daily for 8 weeks, in 11 week (early stage) and 9 month (late stage) male transgenic mice (3 times Transgenic mice PS1

Indexed as

AD biomarkersAICD, APP Intracellular Cytoplasmic/C-terminal DomainAlzheimer's disease (AD)AMPK, 5′ adenosine monophosphate-activated protein kinaseAnimal model of ADAntroquinonolAPP, Amyloid precursor proteinAPPβ, secreted amino-terminals APPβ fragmentAβ, amyloid-β peptidesBehavioural testingcdck5, cyclin dependant kinase 5CTFα, carboxyterminal fragment-αCTFβ, carboxyterminal fragment-βGSK3β, Glycogen synthase kinase 3 betaIFNγ, Interferon gammaIL-1, Interleukin 1IL-6, Interleukin 6Inflammatory markersMAPK, Mitogen activated protein kinaseNF-kB, nuclear factor kappa-light-chain-enhancer of activated B cellsNMDA Rc, methyl-D-aspartate receptors receptorROS, reactive oxygen speciessAPPα, secreted amino-terminals APPα fragmentTNF-α, Tumor Necrosis factor alphaTransgenic mice

Identifiers

PMID35252893
PMCPMC8892093
OpenAlexW4213447995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.